Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

United Therapeutics Drops on Generic Drug: Washington Mover

United Therapeutics Corp. fell as much as 4.7 percent, the biggest intraday decline since November, after the FDA said an unidentified company applied to sell a generic version of its best-selling Remodulin drug.

The U.S. Food & Drug Administration said the application includes a so-called Paragraph IV certification, which means the company is claiming Remodulin patents are invalid or not infringed. The patent doesn’t expire until 2014, though these challenges are typically filed years in advance.

The Silver Spring, Maryland-based company’s stock sank $1.95 to $46.43 at 2:36 p.m. on the Nasdaq Stock Market after dropping as low as $46.12.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.